Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
InnoCare Pharma Ltd. ( (HK:9969) ) has issued an update.
InnoCare Pharma plans to adopt a new 2026 RMB Share Incentive Scheme at its upcoming annual general meeting to strengthen its long-term incentive mechanisms and tie employees’ interests more closely to those of shareholders. The scheme aims to attract and retain key talent, motivate staff, and align core teams with the company’s long-term development.
Shareholders will be asked to approve the scheme, its mandate limit, related assessment measures, the issuance of new RMB shares under it, and authorization for the board to manage its implementation. The company has also secured a one-off waiver from the Hong Kong Stock Exchange so that RMB shares issued under the plan will not require listing in Hong Kong, with certain listing rule requirements modified to apply only to holders of Hong Kong-listed shares.
The most recent analyst rating on (HK:9969) stock is a Buy with a HK$18.31 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
More about InnoCare Pharma Ltd.
InnoCare Pharma Limited is a biopharmaceutical company listed in Hong Kong that focuses on developing and commercializing innovative therapies. The company operates in both the Hong Kong and mainland China capital markets, issuing Hong Kong dollar and RMB-denominated shares to support its growth and incentivize its employees and core teams.
Average Trading Volume: 8,414,109
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$21.04B
Learn more about 9969 stock on TipRanks’ Stock Analysis page.